secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0000950170-25-047206
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Therapeutics reports FY2024 net loss $17.4M, cash $83.6M; SELVA top-line Q1 2026 on track
--------------------------------------------------------------------------------

- Net loss $17.4M ($7.83/share) vs net income $17.9M in FY2023; R&D expense $8.2M, G&A $5.9M.
- Cash and equivalents $83.6M, expected to fund operations into H2 2027.
- Completed merger and $78.9M private placement in Dec 2024 with BVF, Frazier Life Sciences.
- Phase 3 SELVA top-line Q1 2026; Phase 2 TOIVA top-line Q4 2025; both for QTORIN rapamycin.
- Plans to expand QTORIN pipeline with new indication and product candidate in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/0000950170-25-047206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000095017025047206/pvla-20250331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-047206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer